What laboratory tests should be monitored regularly in a patient with chronic kidney disease stage 3 (estimated glomerular filtration rate 30–59 mL/min/1.73 m²)?

Laboratory Monitoring for CKD Stage 3

Patients with CKD stage 3 (eGFR 30–59 mL/min/1.73 m²) require systematic monitoring of kidney function, mineral-bone parameters, anemia, electrolytes, and metabolic acidosis at defined intervals based on disease severity.

Core Monitoring Parameters

Kidney Function and Albuminuria

• Measure eGFR and urinary albumin-to-creatinine ratio (UACR) every 6 months for stage 3a patients (eGFR 45–59) with low-risk albuminuria (UACR <30 mg/g) 1.
• Increase monitoring to every 3–4 months for stage 3b patients (eGFR 30–44) or those with moderate-to-severe albuminuria (UACR ≥30 mg/g), as these patients face substantially higher progression risk 1.
• Always calculate eGFR using validated equations (CKD-EPI 2021) rather than relying on serum creatinine alone, which underestimates CKD severity in older adults 1, 2.

Mineral-Bone Disorder Screening

• Obtain intact parathyroid hormone (PTH), serum calcium, phosphate, and 25-hydroxyvitamin D at least once when eGFR falls below 45 mL/min/1.73 m² (stage 3b), because PTH elevation begins when eGFR drops below 60 3, 1.
• Recheck calcium and phosphorus every 3 months in stage 3b patients 3.
• Monitor iPTH every 3 months if calcium or phosphorus levels become abnormal 3.

Anemia Surveillance

• Check hemoglobin at least once yearly in stage 3a CKD 1, 4.
• Increase hemoglobin monitoring to twice yearly (every 6 months) in stage 3b CKD, as anemia prevalence rises markedly at this stage 3, 1, 4.
• Perform complete iron studies (serum iron, TIBC, ferritin, transferrin saturation) when hemoglobin falls below 12 g/dL in women or 13 g/dL in men 3.

Electrolytes and Acid-Base Status

• Measure serum sodium, potassium, chloride, and bicarbonate every 3–5 months in stage 3b CKD 1.
• Monitor serum bicarbonate at least every 3 months to detect metabolic acidosis; correct chronic acidosis to maintain bicarbonate ≥22 mmol/L 3.
• Intensify potassium monitoring (recheck within 2–4 weeks) after initiating or titrating ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists 1.

Blood Pressure Assessment

• Check blood pressure at every clinic visit, which should occur at least every 3 months for stage 3 CKD 3.
• Monitor blood pressure with each dose if the patient is receiving erythropoietin or an erythropoietin analogue 3.

Nutritional Status

• Measure body weight and serum albumin every 3 months to detect malnutrition early 3.
• Refer for dietary counseling if unintentional weight loss exceeds 5% or serum albumin drops by more than 0.3 g/dL or falls below 4.0 g/dL (Bromo-Cresol-Green assay) 3.

Lipid Profile

• Monitor fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) to screen for dyslipidemias, which are common in CKD and increase cardiovascular risk 3.

Risk-Stratified Monitoring Frequency

Albuminuria (UACR)	Risk Level	eGFR + UACR Monitoring
<30 mg/g	Low	Twice yearly [1]
30–300 mg/g	Moderate-High	Three times yearly [1]
>300 mg/g	Very High	Four times yearly + nephrology referral [1]

Special Considerations for Metformin Users

• Recheck eGFR at least every 3–6 months while patients are on metformin 1.
• Reduce metformin dose by 50% when eGFR is 30–44 mL/min/1.73 m² (stage 3b) 1.
• Discontinue metformin if eGFR declines below 30 mL/min/1.73 m² 1.
• Monitor vitamin B12 levels in patients who have been receiving metformin for more than 4 years 1.

Nephrology Referral Triggers

• Refer immediately if eGFR declines by more than 5 mL/min/1.73 m² per year 1.
• Refer when eGFR approaches 30 mL/min/1.73 m² (transition to stage 4 CKD) 1, 5.
• Refer all patients with UACR >300 mg/g and stage 3b CKD 1.

Common Pitfalls to Avoid

• Do not skip albuminuria testing—eGFR and UACR provide independent prognostic information for cardiovascular events, CKD progression, and mortality 1.
• Do not rely on serum creatinine alone—it systematically underestimates CKD severity, particularly in older adults where 80.6% of those with stage 3 CKD have creatinine ≤1.5 mg/dL 2.
• Do not delay mineral-bone screening until symptoms appear—PTH elevation begins silently when eGFR falls below 60, and early detection allows timely intervention 3, 1.
• Do not overlook metabolic acidosis—chronic acidosis accelerates bone disease and muscle wasting, yet remains asymptomatic until severe 3.